Engrail Therapeutics
PrivateLast Round
Series B
Extension
Aug 8, 2024
Total Funding Raised
$241M
Momentum Score
25 /100
Company Overview
Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing and delivering transformational therapies for patients with neuropsychiatric and neurodevelopmental disorders. Founded in 2019, the company aims to become a leader in neuroscience by uniting biological insights with clinically meaningful solutions. Engrail's pipeline includes treatments for diseases with significant unmet medical needs, such as anxiety disorders, depression, post-traumatic stress disorder (PTSD), and rare neurodegenerative diseases. The company is advancing multiple programs, including its lead asset ENX-102, which is in a Phase 2 study for generalized anxiety disorder. Engrail has raised over $220 million since its inception, including a $157 million Series B round in March 2024, to propel its pipeline through various stages of clinical development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Mental Health, Precision Medicine
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engrail Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Engrail Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Aug 8, 2024 | ||||
| Series B | Mar 19, 2024 | ||||
| Series A Extension | Aug 3, 2021 | ||||
| Series A | Jun 18, 2020 |
Key People
Founding team and executive leadership
Engrail Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| F-Prime Capital | Series B |
| Eight Roads Ventures | Series B |
| Ysios Capital | Series B |
| Nan Fung Life Sciences | Series A Extension, Series A |
| Norwest Venture Partners | Series B |
| RiverVest Venture Partners | Series B |
| Foresite Capital | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2025
ENX-101 evaluated for antiseizure effects in GAERS model.
Engrail Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Engrail Therapeutics's valuation, stock price, and market status.
